Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
In light of evidence supporting enfortumab vedotin with pembrolizumab (EVP) in muscle-invasive urothelial cancer, would one consider perioperative EVP for node-negative high-risk UTUC?
Related Questions
Would you consider omitting adjuvant durvalumab in MIBC to limit overtreatment in patients who may not benefit or those who have achieved maximal benefit after neoadjuvant gem/cis/durva?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
How are you utilizing subcutaneous Nivolumab in genitourinary cancers?
Do you advise patients with a personal or family history of germ cell tumors to avoid endocrine disruptors such as marijuana/CBD, lavender oils, or tea tree oils?
What is your preferred mode of vascular access for testicular cancer regimens?
What would be your recommended regimen for an AYA patient with relapsed mediastinal pure seminoma, with relapse 20 months after completion of BEP?
Do you recommend any alternative schedule for cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?
For patients starting Pluvicto, do you have patients stop their ARPI?
What time frame, number of PSAs, and calculator do you use for calculating PSA doubling times?
How do you interpret NIAGARA efficacy given that adjuvant nivolumab was not administered in the comparator arm?
